Ceritinib following crizotinib relapse for ALK positive NSCLC

Bookmark and Share
Published: 9 Oct 2016
Views: 1386
Dr Giorgio Scagliotti - University of Turin, Turin, Italy

Dr Scagliotti presents, at a press conference at ESMO 2016, results from the ASCEND-5 trial of ceritinib, a kinase inhibitor targeting ALK rearrangements, for patients with advanced non-small cell lung cancer who had relapsed following crizotinib therapy.

He spoke with ecancer about these results, with a video interview available here.

Further details are available in news coverage here.

NSCLC was discussed further in this press conference by Dr Martin Reck, Dr Corey Langer, and Dr Fabrice Barlesi.